Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis (RA)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 270
Healthy volunteers: no

Brief summary:
The purpose of the study is to determine whether subcutaneous abatacept administered to patients with rheumatoid arthritis is associated with increased immunogenicity or increased safety events upon withdrawal and reintroduction.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Abatacept intervention 2: Placebo
Intervention descriptions: intervention 1: Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term) intervention 2: Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)

Protocol document: